Literature DB >> 31931525

Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?

Douglas S Krakower1, Demetre C Daskalakis2, Judith Feinberg3, Julia L Marcus4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31931525      PMCID： PMC7217716          DOI： 10.7326/M19-3337

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  6 in total

1.  Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.

Authors:  Amanda Mocroft; Ole Kirk; Peter Reiss; Stephane De Wit; Dalibor Sedlacek; Marek Beniowski; Jose Gatell; Andrew N Phillips; Bruno Ledergerber; Jens D Lundgren
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

2.  Where Were the Women? Gender Parity in Clinical Trials.

Authors:  Robert H Goldstein; Rochelle P Walensky
Journal:  N Engl J Med       Date:  2019-10-30       Impact factor: 91.245

3.  Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.

Authors:  Willem D F Venter; Michelle Moorhouse; Simiso Sokhela; Lee Fairlie; Nkuli Mashabane; Masebole Masenya; Celicia Serenata; Godspower Akpomiemie; Ambar Qavi; Nomathemba Chandiwana; Shane Norris; Matthew Chersich; Polly Clayden; Elaine Abrams; Natasha Arulappan; Alinda Vos; Kaitlyn McCann; Bryony Simmons; Andrew Hill
Journal:  N Engl J Med       Date:  2019-07-24       Impact factor: 91.245

4.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Authors:  Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

5.  The Epi-TAF for Tenofovir Disoproxil Fumarate?

Authors:  Rochelle P Walensky; Tim H Horn; A David Paltiel
Journal:  Clin Infect Dis       Date:  2015-12-09       Impact factor: 9.079

6.  How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP.

Authors:  Victoria Pilkington; Andrew Hill; Sophie Hughes; Nneka Nwokolo; Anton Pozniak
Journal:  J Virus Erad       Date:  2018-10-01
  6 in total
  10 in total

1.  Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?

Authors:  Alexa B D'Angelo; Drew A Westmoreland; Pedro B Carneiro; Jeremiah Johnson; Christian Grov
Journal:  AIDS Patient Care STDS       Date:  2021-08       Impact factor: 5.944

Review 2.  Data Velocity in HIV-Related Implementation Research: Estimating Time From Funding to Publication.

Authors:  Sheree R Schwartz; Joel Chavez Ortiz; Justin D Smith; Laura K Beres; Aaloke Mody; Ingrid Eshun-Wilson; Nanette Benbow; Deepthi P Mallela; Stephen Tan; Stefan Baral; Elvin Geng
Journal:  J Acquir Immune Defic Syndr       Date:  2022-07-01       Impact factor: 3.771

3.  Association between the geographic accessibility of PrEP and PrEP use among MSM in nonurban areas.

Authors:  J Danielle Sharpe; Travis H Sanchez; Aaron J Siegler; Jodie L Guest; Patrick S Sullivan
Journal:  J Rural Health       Date:  2022-01-07       Impact factor: 5.667

4.  Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.

Authors:  Rochelle P Walensky; Tim Horn; Nicole C McCann; Kenneth A Freedberg; A David Paltiel
Journal:  Ann Intern Med       Date:  2020-03-10       Impact factor: 25.391

Review 5.  Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs.

Authors:  Kinna Thakarar; Katherine Nenninger; Wollelaw Agmas
Journal:  Infect Dis Clin North Am       Date:  2020-09       Impact factor: 5.982

6.  Marketing of Tenofovir Disoproxil Fumarate (TDF) Lawsuits and Social Media Misinformation Campaigns' Impact on PrEP Uptake Among Gender and Sexual Minority Individuals.

Authors:  Christian Grov; Drew A Westmoreland; Alexa B D'Angelo; Jeremiah Johnson; Denis Nash; Demetre C Daskalakis
Journal:  AIDS Behav       Date:  2021-05

7.  Effect of Truvada lawsuit advertising on preexposure prophylaxis attitudes and decisions among sexual and gender minority youth and young adults at risk for HIV.

Authors:  Pedro A Serrano; Elizabeth Daubert; Alejandro Munoz; Sybil G Hosek; Audrey L French
Journal:  AIDS       Date:  2021-01-01       Impact factor: 4.632

8.  Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center.

Authors:  Julia L Marcus; Kenneth Levine; Whitney C Sewell; Patricia Solleveld; Kenneth H Mayer; Douglas S Krakower
Journal:  Open Forum Infect Dis       Date:  2021-08-05       Impact factor: 3.835

9.  PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men.

Authors:  Gabriel Robles; Daniel Sauermilch; Monica Gandhi; Tyrel J Starks
Journal:  AIDS Behav       Date:  2020-11-18

Review 10.  Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review.

Authors:  Sheldon D Fields; Elyse Tung
Journal:  Infect Dis Ther       Date:  2021-02-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.